Leptin’s Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals
Leptin is an adipocyte-secreted hormone that has been proposed to regulate energy homeostasis as well as meta- bolic, reproductive, neuroendocrine, and immune functions. In the context of open-label uncontrolled studies, leptin administration has demonstrated insulin-sensitizing effects in patients with congenital lipodystrophy associated with relative leptin deficiency. Leptin administration has also been shown to decrease central fat mass and improve insulin sensitivity and fasting insulin and glucose levels in HIV-infected patients with highly active antiretroviral therapy (HAART)-induced lipodystrophy, insulin resistance, and leptin deficiency. On the contrary, the effects of leptin treatment in leptin-replete or hyperleptinemic obese individuals with glucose intolerance and diabetes mel- litus have been minimal or null, presumably due to leptin tolerance or resistance that impairs leptin action. Similarly, experimental evidence suggests a null or a possibly adverse role of leptin treatment in nonlipodystrophic patients with nonalcoholic fatty liver disease. In this review, we present a description of leptin biology and signaling; we summarize leptin’s contribution to glucose metabolism in animals and humans in vitro, ex vivo, and in vivo; and we provide insights into the emerging clinical applications and therapeutic uses of leptin in humans with lipodystrophy and/or diabetes. (Endocrine Reviews 34: 377– 412, 2013)
Leptin is an adipocyte-secreted hormone that has been proposed to regulate energy homeostasis as well as meta- bolic, reproductive, neuroendocrine, and immune functions. In the context of open-label uncontrolled studies, leptin administration has demonstrated insulin-sensitizing effects in patients with congenital lipodystrophy associated with relative leptin deficiency. Leptin administration has also been shown to decrease central fat mass and improve insulin sensitivity and fasting insulin and glucose levels in HIV-infected patients with highly active antiretroviral therapy (HAART)-induced lipodystrophy, insulin resistance, and leptin deficiency. On the contrary, the effects of leptin treatment in leptin-replete or hyperleptinemic obese individuals with glucose intolerance and diabetes mel- litus have been minimal or null, presumably due to leptin tolerance or resistance that impairs leptin action. Similarly, experimental evidence suggests a null or a possibly adverse role of leptin treatment in nonlipodystrophic patients with nonalcoholic fatty liver disease. In this review, we present a description of leptin biology and signaling; we summarize leptin’s contribution to glucose metabolism in animals and humans in vitro, ex vivo, and in vivo; and we provide insights into the emerging clinical applications and therapeutic uses of leptin in humans with lipodystrophy and/or diabetes. (Endocrine Reviews 34: 377– 412, 2013)
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
410 Moon et al Effects of Leptin on Glucose Metabolism Endocrine Reviews, June 2013, 34(3):377–412
improves highly active antiretroviral therapy-induced lipoatrophy
and the metabolic syndrome, but not through
altering circulating IGF and IGF-binding protein levels:
observational and interventional studies in humans. Eur J
Endocrinol. 2009;160:173–176.
230. Yarasheski KE, Zachwieja JJ, Horgan MM, Powderly
WG, Santiago JV, Landt M. Serum leptin concentrations in
human immunodeficiency virus-infected men with low adiposity.
Metab Clin Exp. 1997;46:303–305.
231. Nagy GS, Tsiodras S, Martin LD, et al. Human immunodeficiency
virus type 1-related lipoatrophy and lipohypertrophy
are associated with serum concentrations of leptin.
Clin Infect Dis. 2003;36:795–802.
232. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer
AW, Mantzoros CS. Hypoadiponectinemia is associated
with insulin resistance, hypertriglyceridemia, and fat redistribution
in human immunodeficiency virus-infected
patients treated with highly active antiretroviral therapy.
J Clin Endocrinol Metab. 2003;88:627–636.
233. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros
CS. Recombinant methionyl human leptin therapy in replacement
doses improves insulin resistance and metabolic
profile in patients with lipoatrophy and metabolic syndrome
induced by the highly active antiretroviral therapy.
J Clin Endocrinol Metab. 2006;91:2605–2611.
234. Mulligan K, Khatami H, Schwarz JM, et al. The effects of
recombinant human leptin on visceral fat, dyslipidemia,
and insulin resistance in patients with human immunodeficiency
virus-associated lipoatrophy and hypoleptinemia.
J Clin Endocrinol Metab. 2009;94:1137–1144.
235. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon
S. Metformin in the treatment of HIV lipodystrophy
syndrome: a randomized controlled trial. JAMA. 2000;
284:472–477.
236. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon
S. Metabolic effects of rosiglitazone in HIV lipodystrophy:
a randomized, controlled trial. Ann Intern
Med. 2004;140:786–794.
237. Sekhar RV, Jahoor F, Iyer D, et al. Leptin replacement
therapy does not improve the abnormal lipid kinetics of
hypoleptinemic patients with HIV-associated lipodystrophy
syndrome. Metabolism. 2012;61:1395–1403
238. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth
hormone-releasing factor in patients with HIV. N Engl
J Med. 2007;357:2359–2370.
239. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin
(TH9507), a growth hormone-releasing factor analog,
in human immunodeficiency virus-infected patients
with excess abdominal fat: a pooled analysis of two multicenter,
double-blind placebo-controlled phase 3 trials
with safety extension data. J Clin Endocrinol Metab. 2010;
95:4291–4304.
240. Tong Q, Sankalé JL, Hadigan CM. Regulation of adiponectin
in human immunodeficiency virus-infected patients:
relationship to body composition and metabolic indices.
J Clin Endocrinol Metab. 2003;88:1559–1564.
241. Vigouroux C, Maachi M, Nguyên TH. Serum adipocytokines
are related to lipodystrophy and metabolic disorders
in HIV-infected men under antiretroviral therapy. AIDS.
2003;17:1503–1511.
242. Mynarcik DC, Combs T, McNurlan MA, Scherer PE,
Komaroff E, Gelato MC. Adiponectin and leptin levels in
HIV-infected subjects with insulin resistance and body fat
redistribution. J Acquir Immune Defic Syndr. 2002;31:
514–520.
243. Duntas LH, Popovic V, Panotopoulos G. Adiponectin:
novelties in metabolism and hormonal regulation. Nutr
Neurosci. 2004;7:195–200.
244. Yamauchi T, Kamon J, Waki H, et al. The fat-derived
hormone adiponectin reverses insulin resistance associated
with both lipoatrophy and obesity. Nat Med. 2001;7:941–
946.
245. Gavrila A, Hsu W, Tsiodras S, et al. Improvement in highly
active antiretroviral therapy-induced metabolic syndrome by
treatment with pioglitazone but not with fenofibrate: a 2 2
factorial, randomized, double-blinded, placebo-controlled
trial. Clin Infect Dis. 2005;40:745–749.
246. Magkos F, Brennan A, Sweeney L, et al. Leptin replacement
improves postprandial glycemia and insulin sensitivity
in human immunodeficiency virus-infected lipoatrophic
men treated with pioglitazone: a pilot study. Metab
Clin Exp. 2011;60:1045–1049.
247. Chou SH, Chamberland JP, Liu X, et al. Leptin is an effective
treatment for hypothalamic amenorrhea. Proc Natl
Acad Sci U S A. 2011;108:6585–6590.
248. Sienkiewicz E, Magkos F, Aronis KN, et al. Long-term
metreleptin treatment increases bone mineral density and
content at the lumbar spine of lean hypoleptinemic women.
Metabolism. 2011;60:1211–1221.
249. Welt CK, Chan JL, Bullen J, et al. Recombinant human
leptin in women with hypothalamic amenorrhea. N Engl
J Med. 2004;351:987–997.
250. Harris RB, Mitchell TD, Hebert S. Leptin-induced changes
in body composition in high fat-fed mice. Exp Biol Med
(Maywood). 2003;228:24–32.
251. Buettner R, Newgard CB, Rhodes CJ, O’Doherty RM.
Correction of diet-induced hyperglycemia, hyperinsulinemia,
and skeletal muscle insulin resistance by moderate
hyperleptinemia. Am J Physiol Endocrinol Metab. 2000;
278:563–569.
252. Harris RB, Mitchell TD, Yan X, Simpson JS, Redmann SM
Jr. Metabolic responses to leptin in obese db/db mice are
strain dependent. Am J Physiol Regul Integr Comp
Physiol. 2001;281:R115–R132.
253. Mantzoros CS, Frederich RC, Qu D, Lowell BB, Maratos-
Flier E, Flier JS. Severe leptin resistance in brown
fat-deficient uncoupling protein promoter-driven diphtheria
toxin A mice despite suppression of hypothalamic neuropeptide
Y and circulating corticosterone concentrations.
Diabetes. 1998;47:230–238.
254. Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid
AR, Smith FJ, Campfield LA. Weekly subcutaneous pegylated
recombinant native human leptin (PEG-OB) administration
in obese men. J Clin Endocrinol Metab. 2000;85:
4003–4009.
255. Rahmouni K, Haynes WG. Leptin and the cardiovascular
system. Recent Prog Horm Res. 2004;59:225–244.
256. Hukshorn CJ, van Dielen FM, Buurman WA, Westerterp-
Plantenga MS, Campfield LA, Saris WH. The effect of
pegylated recombinant human leptin (PEG-OB) on weight
loss and inflammatory status in obese subjects. Int J Obes
Relat Metab Disord. 2002;26:504–509.
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 10 June 2014. at 01:44 For personal use only. No other uses without permission. . All rights reserved.
Change language